NICE Updates Type 2 Diabetes Guidance for Earlier SGLT-2 Inhibitor Use; SGLT2 Inhibitors Also Linked to Survival Benefit in Takotsubo Syndrome
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.